KR100909640B1 - 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법 - Google Patents

결핵의 면역치료 및 진단용 화합물과 이의 사용 방법 Download PDF

Info

Publication number
KR100909640B1
KR100909640B1 KR1020077003582A KR20077003582A KR100909640B1 KR 100909640 B1 KR100909640 B1 KR 100909640B1 KR 1020077003582 A KR1020077003582 A KR 1020077003582A KR 20077003582 A KR20077003582 A KR 20077003582A KR 100909640 B1 KR100909640 B1 KR 100909640B1
Authority
KR
South Korea
Prior art keywords
ala
gly
seq
gln
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077003582A
Other languages
English (en)
Korean (ko)
Other versions
KR20070026886A (ko
Inventor
마크 알 앨더슨
다빈 씨 딜론
야시 에이 더블유 스케이키
안토니오 캠포스-네토
Original Assignee
코리사 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코리사 코퍼레이션 filed Critical 코리사 코퍼레이션
Publication of KR20070026886A publication Critical patent/KR20070026886A/ko
Application granted granted Critical
Publication of KR100909640B1 publication Critical patent/KR100909640B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020077003582A 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법 Expired - Fee Related KR100909640B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85938197A 1997-05-20 1997-05-20
US08/859,381 1997-05-20
US09/073,010 US6613881B1 (en) 1997-05-20 1998-05-05 Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US09/073,010 1998-05-05
PCT/US1998/010407 WO1998053075A2 (en) 1997-05-20 1998-05-20 Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010257A Division KR100893118B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20070026886A KR20070026886A (ko) 2007-03-08
KR100909640B1 true KR100909640B1 (ko) 2009-07-27

Family

ID=26754016

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020077003582A Expired - Fee Related KR100909640B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법
KR1019997010775A Expired - Fee Related KR100652513B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법
KR1020067010257A Expired - Fee Related KR100893118B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법
KR1020087007618A Expired - Fee Related KR100924475B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1019997010775A Expired - Fee Related KR100652513B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법
KR1020067010257A Expired - Fee Related KR100893118B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법
KR1020087007618A Expired - Fee Related KR100924475B1 (ko) 1997-05-20 1998-05-20 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법

Country Status (20)

Country Link
US (1) US6613881B1 (https=)
EP (4) EP2172551A3 (https=)
JP (4) JP4162155B2 (https=)
KR (4) KR100909640B1 (https=)
AT (1) ATE420180T1 (https=)
AU (1) AU742751B2 (https=)
BR (1) BR9809445A (https=)
CA (2) CA2783134A1 (https=)
CZ (2) CZ303194B6 (https=)
DE (1) DE69840449D1 (https=)
DK (1) DK1012293T3 (https=)
ES (1) ES2321039T3 (https=)
HU (1) HU226520B1 (https=)
IL (2) IL133056A0 (https=)
NO (4) NO324880B1 (https=)
NZ (1) NZ501310A (https=)
PL (1) PL191121B1 (https=)
PT (1) PT1012293E (https=)
TR (1) TR200000115T2 (https=)
WO (1) WO1998053075A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
CA2319380A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030027774A1 (en) * 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP5010079B2 (ja) 1999-07-13 2012-08-29 スタテンズ セーラム インスティテュート マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
AU2001250294A1 (en) * 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
WO2005118884A1 (en) * 2004-05-28 2005-12-15 The United States Of America As Represented By The Secretary Of The Navy A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines
US8475735B2 (en) * 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
CN102220357B (zh) * 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
WO2006117538A2 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
WO2007041539A1 (en) * 2005-09-30 2007-04-12 Transcutaneous Technologies, Inc. Iontophoresis apparatus and method for the diagnosis of tuberculosis
EP2441469A1 (en) 2006-03-14 2012-04-18 Oregon Health and Science University Methods for producing an immune response to tuberculosis
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
GB201012072D0 (en) * 2010-07-19 2010-09-01 Sec Dep For Environment Food A Diagnostic reagents
WO2012177656A2 (en) 2011-06-19 2012-12-27 Abogen, Inc. Devices, solutions and methods for sample collection
US12038434B2 (en) 2015-02-09 2024-07-16 DNA Genotek, Inc. Devices, solutions and methods for sample collection related applications, analysis and diagnosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4689397A (en) 1985-08-12 1987-08-25 Scripps Clinic And Research Foundation Synthetic polypeptides for detecting mycobacterial infections
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US4976958A (en) * 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5330754A (en) 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
EP0736098A1 (en) * 1993-12-23 1996-10-09 Agresearch New Zealand Pastoral Agriculture Research Institute, Ltd. Mycobacteria virulence factors and a method for their identification
IE960132A1 (en) * 1995-03-13 1996-09-18 Astra Ab New DNA molecules
AU727602B2 (en) 1995-09-01 2000-12-14 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
CA2230927A1 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
BR9712298A (pt) * 1996-10-11 2000-10-24 Corixa Corp Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
국제특허공보 97/09428 A2 (1997.03.13. 공고)

Also Published As

Publication number Publication date
EP1012293A2 (en) 2000-06-28
PT1012293E (pt) 2009-04-08
PL337330A1 (en) 2000-08-14
EP2248900A1 (en) 2010-11-10
JP4759010B2 (ja) 2011-08-31
KR20080036663A (ko) 2008-04-28
KR20070026886A (ko) 2007-03-08
ATE420180T1 (de) 2009-01-15
CZ410099A3 (cs) 2000-05-17
CZ300866B6 (cs) 2009-08-26
JP2008253260A (ja) 2008-10-23
HU226520B1 (en) 2009-03-30
AU7690798A (en) 1998-12-11
NO20075901L (no) 2000-01-18
KR20060066139A (ko) 2006-06-15
JP2008283961A (ja) 2008-11-27
NO995689L (no) 2000-01-18
DK1012293T3 (da) 2009-05-04
TR200000115T2 (tr) 2000-11-21
JP4759011B2 (ja) 2011-08-31
AU742751B2 (en) 2002-01-10
NO324880B1 (no) 2007-12-27
WO1998053075A3 (en) 1999-04-01
KR100652513B1 (ko) 2006-12-01
NO995689D0 (no) 1999-11-19
CZ303194B6 (cs) 2012-05-23
NZ501310A (en) 2001-09-28
US6613881B1 (en) 2003-09-02
EP2248900B1 (en) 2012-07-18
EP2270170B1 (en) 2013-11-06
JP2002514084A (ja) 2002-05-14
ES2321039T3 (es) 2009-06-01
BR9809445A (pt) 2000-06-13
CA2783134A1 (en) 1998-11-26
IL133056A0 (en) 2001-03-19
DE69840449D1 (de) 2009-02-26
CA2290774A1 (en) 1998-11-26
JP2008245644A (ja) 2008-10-16
PL191121B1 (pl) 2006-03-31
EP2270170A1 (en) 2011-01-05
KR100893118B1 (ko) 2009-04-14
NO20075902L (no) 2000-01-18
KR20010012812A (ko) 2001-02-26
EP2172551A2 (en) 2010-04-07
JP4764445B2 (ja) 2011-09-07
JP4162155B2 (ja) 2008-10-08
IL133056A (en) 2010-11-30
KR100924475B1 (ko) 2009-11-03
EP1012293B1 (en) 2009-01-07
HUP0003402A3 (en) 2001-03-28
EP2172551A3 (en) 2010-11-10
NO20075900L (no) 2000-01-18
HUP0003402A2 (hu) 2000-12-28
WO1998053075A2 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
KR100909640B1 (ko) 결핵의 면역치료 및 진단용 화합물과 이의 사용 방법
US6555653B2 (en) Compounds for diagnosis of tuberculosis and methods for their use
US20020098200A1 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
CA2268008A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
CA2405247A1 (en) Tuberculosis antigens and methods of use thereof
US20020081579A1 (en) Method for the isolation of novel antigens
ES2445209T3 (es) Compuestos para inmunoterapia y diagnóstico de la tuberculosis y métodos de su uso
HK1150852A (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
HK1148775A (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
HK1142098A (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20120722

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120722

St.27 status event code: N-4-6-H10-H13-oth-PC1903